Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Effect of nintedanib in patients with systemic sclerosis‑associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial
Khanna D et al.
Efficacy and safety of nintedanib in patients with systemic sclerosis‑associated ILD (SSc‑ILD) and differing comorbidity burden: subgroup analyses of the SENSCIS trial
Highland KB et al.
Effect of nintedanib on KL‑6 in patients with systemic sclerosis‑associated interstitial lung disease in the SENSCIS trial
Assassi S et al.
Esophageal involvement and gastroesophageal reflux disease in patients with SSc‑ILD: data from a sub‑study of the SENSCIS trial
Kreuter M et al.
Continued treatment with nintedanib in patients with systemic sclerosis‑associated interstitial lung disease (SSc‑ILD): two‑year data from SENSCIS‑ON
Allanore Y et al.
Severity and impact of gastrointestinal symptoms in patients with SSc‑ILD treated with nintedanib: data from SENSCIS‑ON
Khanna D et al.
SC-ES-08021